Substance / Medication

Rizatriptan

Overview

Active Ingredient
rizatriptan
RxNorm CUI
88014

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
1
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Ten years of rizatriptan: from development to clinical science and future directions.
Hargreaves Richard J, Lines Chris R, Rapoport Alan M et al. · Headache · 2009
PMID: 19161563Meta-Analysis
WITHDRAWN: Rizatriptan for acute migraine.
Oldman A D, Smith L A, McQuay H J et al. · Cochrane Database Syst Rev · 2007
PMID: 17636717Meta-AnalysisFull text (PMC)
Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack Paul L, Foster Rachel H · Pharmacoeconomics · 2005
PMID: 16336021Meta-Analysis
Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials.
Ferrari M D, Loder E, McCarroll K A et al. · Cephalalgia · 2001
PMID: 11422095Meta-Analysis
Rizatriptan for acute migraine.
Oldman A D, Smith L A, McQuay H J et al. · Cochrane Database Syst Rev · 2001
PMID: 11687054Meta-Analysis
Rizatriptan vs Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial.
Staab Jeffrey P, Eggers Scott D Z, Jen Joanna C et al. · JAMA Neurol · 2025
PMID: 40354049RCTFull text (PMC)
A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence.
Tellone Valeria, Dragone Patrizia, Picollo Rossella et al. · Int J Clin Pharmacol Ther · 2020
PMID: 32716291RCT
Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial.
Barbanti Piero, Fofi Luisa, Dall'Armi Valentina et al. · J Headache Pain · 2012
PMID: 22460943RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rizatriptan (substance)
SNOMED CT
363573000
UMLS CUI
C0297635
RxNorm CUI
88014

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Rizatriptan — Conditions, Biomarkers & Specialists | Ltrl | Ltrl